IMB Dx, Inc. (KOSDAQ: A461030)
Health Care · Biotechnology · KR
₩2,605.00
-8.44% today · -76.3% 1Y
IMB Dx, Inc. (KOSDAQ: A461030) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.39M.
Over the last twelve months the share price has lost 76.3%, trading between 1.91K and 12.99K.
Tweenvest scores IMB Dx, Inc. across four factors: quality 39/100, value 34/100. Its strongest factor is quality.
A461030 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.39M
- Revenue (TTM)
- $3.62M
- P/E
- —
- EPS
- -537.84
- Dividend yield
- —
- Beta (5Y)
- 0.51
- 52-week high
- ₩12,990.00
- 52-week low
- ₩1,910.00
- Avg volume (3M)
- —
- Shares outstanding
- 14.02M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Matricelf LtdTASE: MTLF | $27.79M | ₪2.60 | +4.20% |
| Zenotech Laboratories LimitedBSE: 532039 | $27.69M | Rs43.06 | -0.02% |
| Kohjin Bio Co., Ltd.TSE: 177A | $27.45M | ¥848.00 | +4.05% |
| Chordia Therapeutics Inc.TSE: 190A | $27.40M | ¥56.00 | -1.75% |
| LabGenomics Co., Ltd.KOSDAQ: A084650 | $27.17M | ₩2,440.00 | -12.07% |
| Isofol Medical AB (publ)OM: ISOFOL | $26.73M | Skr0.83 | +3.51% |
| Kim Forest Enterprise Co., Ltd.TWSE: 6645 | $26.71M | NT$14.35 | +6.30% |
| Atossa Therapeutics, Inc.NasdaqCM: ATOS | $25.95M | $2.60 | -4.41% |
Figures last refreshed Oct 18, 2026.